RENVELA Side Effects

7006034-5 | Dementia, Oral Administration Complication
on Sep 08, 2010 Female patient from UNITED STATES , 79 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). Patient experienced the following unwanted or unexpected effects: dementia (What is dementia?), oral administration complication. Renvela dosage: Unk.

6699080-2 | Foreign Body Aspiration, Oral Administration Complication, Urine Output Decreased
Patient was taking Renvela (View Usage). Patient had the following side effects: foreign body aspiration, oral administration complication, urine output decreased on Apr 15, 2010 from UNITED STATES Additional patient health information: Female patient , 88 years of age, was diagnosed with hyperphosphataemia and. Renvela dosage: 1.6 G, Tid. Patient was hospitalized.

6609291-X | Cerebrovascular Accident, Dysphagia, Hyperphosphataemia
Adverse event was reported on Feb 11, 2010 by a Male patient taking Renvela (View Usage) (Dosage: 0.8g, Tid, Oral) was diagnosed with hyperphosphataemia and. Location: UNITED STATES , 84 years of age, After Renvela was administered, patient had the following side effects: cerebrovascular accident, dysphagia, hyperphosphataemia. During the same period patient was treated with RENAGEL (Oral) (View Renagel Review and Renagel Label ). Patient was hospitalized.

6540390-7 | Cardiac Arrest, Refusal Of Treatment By Patient
on Jan 04, 2010 Male patient from UNITED STATES , 84 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac arrest (What is cardiac arrest?), refusal of treatment by patient. Renvela dosage: 0.8 G, Tid, Oral.


6537030-X |
on Dec 30, 2009 Female patient from UNITED STATES , 65 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). . Renvela dosage: 0.8 G, Tid, Oral.

6532157-0 | Abdominal Pain, Nausea
Patient was taking Renvela (View Usage). After Renvela was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), nausea (What is nausea?) on Jun 18, 2009 from UNITED STATES Additional patient health information: Female patient , 38 years of age, was diagnosed with hyperphosphataemia and. Renvela dosage: 4.8 G, Tid, Oral. During the same period patient was treated with RENAGEL (Oral) (View Renagel Review and Renagel Label ). Patient was hospitalized.

6526205-1 | Cardiac Arrest, Refusal Of Treatment By Patient
Adverse event was reported on Dec 10, 2009 by a Male patient taking Renvela (View Usage) (Dosage: 0.8, Tid, Oral) was diagnosed with hyperphosphataemia and. Location: UNITED STATES , 84 years of age, Patient experienced the following unwanted or unexpected effects: cardiac arrest (What is cardiac arrest?), refusal of treatment by patient.

6526204-X | Cerebrovascular Accident, Dysphagia, Hyperphosphataemia
on Dec 16, 2009 Male patient from UNITED STATES , 84 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). Patient had the following side effects: cerebrovascular accident, dysphagia, hyperphosphataemia. Renvela dosage: 0.8 G, Tid, Oral. During the same period patient was treated with RENAGEL (Oral) (View Renagel Review and Renagel Label ). Patient was hospitalized.

6504770-8 |
on Dec 01, 2009 Female patient from UNITED STATES , 66 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). . Renvela dosage: 4.8 G, Tid, Oral.

6472229-2 | Hyperadrenalism, Hypophagia, Nephrocalcinosis, Renal Hypoplasia, Subileus
Patient was taking Renvela (View Usage). Patient experienced the following unwanted or unexpected effects: hyperadrenalism, hypophagia, nephrocalcinosis, renal hypoplasia, subileus on Nov 12, 2009 from GERMANY Additional patient health information: Female patient , 60 years of age, weighting 136.7 lb, was diagnosed with hyperphosphataemia and. Renvela dosage: 2.4 G, Qd, Oral. During the same period patient was treated with LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), DREISAVIT (ASCORBIC ACID, CALCIUM PANTOTHENATE, FOLIC ACID, NICOTINAMI (View Dreisavit (ascorbic Acid, Calcium Pantothenate, Folic Acid, Nicotinami Review and Dreisavit (ascorbic Acid, Calcium Pantothenate, Folic Acid, Nicotinami Label ), FERRLECIT (View Ferrlecit Review and Ferrlecit Label ), NEORECORMON (EPOETIN BETA) (View Neorecormon (epoetin Beta) Review and Neorecormon (epoetin Beta) Label ). Patient was hospitalized.

6472226-7 | Adrenal Disorder, Nephrolithiasis, Osteolysis, Subileus
Adverse event was reported on Nov 12, 2009 by a Female patient taking Renvela (View Usage) (Dosage: 2.4 G, Qd, Oral) was diagnosed with hyperphosphataemia and. Location: GERMANY , 60 years of age, weighting 136.7 lb, Patient had the following side effects: adrenal disorder, nephrolithiasis, osteolysis, subileus. During the same period patient was treated with LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), DREISAVIT ASCORBIC ACID, CALCIUM PANTOTHENATE, FOLIC ACID, NICOTINAMID (View Dreisavit Ascorbic Acid, Calcium Pantothenate, Folic Acid, Nicotinamid Review and Dreisavit Ascorbic Acid, Calcium Pantothenate, Folic Acid, Nicotinamid Label ), FERRLECIT (View Ferrlecit Review and Ferrlecit Label ), NEORECORMON (EPOTIN BETA) (View Neorecormon (epotin Beta) Review and Neorecormon (epotin Beta) Label ). Patient was hospitalized.

6467522-3 | Ovarian Cancer
on Nov 18, 2009 Female patient from UNITED STATES , 70 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). After Renvela was administered, patient had the following side effects: ovarian cancer. Renvela dosage: 4.0 G, Qd, Oral.

6467521-1 |
on Nov 13, 2009 Male patient from UNITED STATES , 84 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). . Renvela dosage: 12.8 G, Qd, Oral.

6467520-X |
Patient was taking Renvela (View Usage). on Nov 12, 2009 from UNITED STATES Additional patient health information: Female patient , 50 years of age, was diagnosed with hyperphosphataemia and. Renvela dosage: 1.6 G, Tid, Oral.

6456540-7 | Chest Discomfort, Lip Swelling, Urticaria
Adverse event was reported on Nov 10, 2009 by a Female patient taking Renvela (View Usage) (Dosage: 1.6 G, Tid, Oral) was diagnosed with hyperphosphataemia and. Location: DENMARK , 55 years of age, After Renvela was administered, patient had the following side effects: chest discomfort, lip swelling, urticaria. Patient was hospitalized.

6428101-7 | Osteolysis, Subileus
on Oct 19, 2009 Female patient from GERMANY , 60 years of age, weighting 136.7 lb, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). Patient experienced the following unwanted or unexpected effects: osteolysis, subileus. Renvela dosage: Sachet Once A Day, Oral. During the same period patient was treated with L THYROXINE (LEVOTHYROXINE) (View L-thyroxine (levothyroxine) Review and L-thyroxine (levothyroxine) Label ). Patient was hospitalized.

6427189-7 | Cardiac Arrest, Hyperkalaemia
on Oct 21, 2009 Female patient from UNITED STATES , 73 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). Patient had the following side effects: cardiac arrest (What is cardiac arrest?), hyperkalaemia. Renvela dosage: 2.4 G, Tid, Oral; 0.8 G, Bid, Oral. During the same period patient was treated with NEURONTIN (View Neurontin Review and Neurontin Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), ROPINIROLE (View Ropinirole Review and Ropinirole Label ), SYNTHROID (View Synthroid Review and Synthroid Label ).

6415831-6 |
Patient was taking Renvela (View Usage). on Oct 13, 2009 from UNITED STATES Additional patient health information: Female patient , 70 years of age, was diagnosed with hyperphosphataemia and. Renvela dosage: 4.0 Q, Qd, Oral.

6407861-5 |
Adverse event was reported on Oct 01, 2009 by a Female patient taking Renvela (View Usage) (Dosage: 2.4 G, Tid, Oral; 0.8 G, Bid, Oral) was diagnosed with hyperphosphataemia and. Location: UNITED STATES , 73 years of age, .

6377749-7 | Tetany
on Sep 08, 2009 Male patient from UNITED STATES , 52 years of age, weighting 191.8 lb, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). Patient had the following side effects: tetany. Renvela dosage: Oral. Patient was hospitalized.

6337054-1 | Cystitis, Pain
on Aug 21, 2009 Male patient from UNITED STATES , 78 years of age, weighting 165.8 lb, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). After Renvela was administered, patient had the following side effects: cystitis, pain (What is pain?). Renvela dosage: 0.8 G, Qid, Oral. During the same period patient was treated with COUMADIN (View Coumadin Review and Coumadin Label ), ERGOCALCIFEROL (View Ergocalciferol Review and Ergocalciferol Label ), TERAZOSIN HCL (View Terazosin Hcl Review and Terazosin Hcl Label ), SPIRIVA (View Spiriva Review and Spiriva Label ), NASONEX (View Nasonex Review and Nasonex Label ), COMBIVENT (View Combivent Review and Combivent Label ), NEPHRO VITE (VITAMINS NOS) (View Nephro-vite (vitamins Nos) Review and Nephro-vite (vitamins Nos) Label ). Patient was hospitalized.

6326928-3 | Aortic Aneurysm, Hypophosphataemia
Patient was taking Renvela (View Usage). Patient experienced the following unwanted or unexpected effects: aortic aneurysm (What is aortic aneurysm?), hypophosphataemia on Aug 14, 2009 from UNITED KINGDOM Additional patient health information: Male patient , 73 years of age, weighting 235.9 lb, was diagnosed with hyperphosphataemia and. Renvela dosage: 1600 Mg, Tid, Oral, 800 Mg, Tid. During the same period patient was treated with PERINDOPRIL ERBUMINE (View Perindopril Erbumine Review and Perindopril Erbumine Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), DOXAZOSIN MESYLATE (View Doxazosin Mesylate Review and Doxazosin Mesylate Label ), BENDROFLUAZIDE (BENDROGLUMETHIAZIDE) (View Bendrofluazide (bendroglumethiazide) Review and Bendrofluazide (bendroglumethiazide) Label ).

6284584-7 | Cystitis
Adverse event was reported on Jul 13, 2009 by a Male patient taking Renvela (View Usage) (Dosage: 0.8 G, Qid, Oral) was diagnosed with hyperphosphataemia and. Location: UNITED STATES , 78 years of age, Patient had the following side effects: cystitis. Patient was hospitalized.

6241979-5 | Gastroenteritis
on Jun 01, 2009 Female patient from UNITED STATES , 80 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). After Renvela was administered, patient had the following side effects: gastroenteritis (What is gastroenteritis?). Renvela dosage: 8.0 G, Qd, Oral, Oral. During the same period patient was treated with RENAGEL (View Renagel Review and Renagel Label ). Patient was hospitalized.

6193881-5 | Brain Neoplasm, Hypophagia
on May 05, 2009 Male patient from UNITED STATES , 76 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). Patient experienced the following unwanted or unexpected effects: brain neoplasm, hypophagia. Renvela dosage: Oral. During the same period patient was treated with RENAGEL (Oral) (View Renagel Review and Renagel Label ). Patient was hospitalized.

6181943-8 | Gastroenteritis
Patient was taking Renvela (View Usage). Patient had the following side effects: gastroenteritis (What is gastroenteritis?) on Apr 21, 2009 from UNITED STATES Additional patient health information: Female patient , 80 years of age, was diagnosed with hyperphosphataemia and. Renvela dosage: 8.0 G, Qd, Oral, Oral. During the same period patient was treated with RENAGEL (View Renagel Review and Renagel Label ). Patient was hospitalized.

6033050-2 | Choking, Dysphagia, Herpes Zoster, Oral Administration Complication
Adverse event was reported on Dec 26, 2008 by a Female patient taking Renvela (View Usage) (Dosage: 0.8 G, Tid, Oral) was diagnosed with hyperphosphataemia and. Location: UNITED STATES , 77 years of age, After Renvela was administered, patient had the following side effects: choking (What is choking?), dysphagia, herpes zoster, oral administration complication. During the same period patient was treated with RENAGEL (Oral) (View Renagel Review and Renagel Label ). Patient was hospitalized.

6032462-0 | Herpes Zoster, Oral Administration Complication
on Dec 26, 2008 Female patient from UNITED STATES , 77 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). Patient experienced the following unwanted or unexpected effects: herpes zoster, oral administration complication. Renvela dosage: 0.8 G, Tid, Oral. During the same period patient was treated with RENAGEL (Oral) (View Renagel Review and Renagel Label ). Patient was hospitalized.

6031481-8 | Abdominal Pain, Diarrhoea, Vomiting
on Jun 29, 2008 Female patient from UNITED STATES , 80 years of age, was diagnosed with hyperphosphataemia and was treated with Renvela (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), diarrhoea, vomiting. Renvela dosage: 8.0 G, Qd, Oral. During the same period patient was treated with RENAGEL (View Renagel Review and Renagel Label ). Patient was hospitalized.

5897178-X | Intestinal Fistula, Intestinal Obstruction, Intestinal Perforation, Peritonitis, Post Procedural Complication
Patient was taking Renvela (View Usage). After Renvela was administered, patient had the following side effects: intestinal fistula, intestinal obstruction, intestinal perforation, peritonitis, post procedural complication on Sep 09, 2008 from UNITED STATES Additional patient health information: Male patient , 45 years of age, was diagnosed with hyperphosphataemia and. Renvela dosage: 0.8 G, Qd, Oral. During the same period patient was treated with RENAGEL (View Renagel Review and Renagel Label ).

5848489-5 | Asthenia, Diarrhoea, Intestinal Obstruction, Intestinal Perforation, Nausea, Pyrexia
Adverse event was reported on Aug 15, 2008 by a Male patient taking Renvela (View Usage) (Dosage: 800 Mg Tid With Meals Po, {30 Days) was diagnosed with renal failure chronic and. Location: UNITED STATES , 46 years of age, weighting 141.1 lb, Patient experienced the following unwanted or unexpected effects: asthenia, diarrhoea, intestinal obstruction, intestinal perforation, nausea (What is nausea?), pyrexia. During the same period patient was treated with ATENOLOL (View Atenolol Review and Atenolol Label ). Patient was hospitalized.